Biopharma Market’s Green Shoots Are Evident But Full Recovery Must Wait Awhile
Learning To Weather Tough Times Can Deliver Valuable Long-Term Benefits
Biopharma markets may follow the downward trajectory of tech during tough times, but they also chase it back up the value curve. Recovery is just a matter of time, says Seventure’s Isabelle de Crémoux in this commentary on investment trends, the financial markets and the VC environment.
